Neuronetics (STIM) Q1 2026 earnings review
Clinic Growth Masks Legacy Weakness as Margins Compress
Neuronetics delivered an 8% YoY revenue increase to $34.5 million in Q1 2026, driven entirely by its acquired Greenbrook clinic business. However, the legacy core engine is stalling: U.S. treatment session revenue reversed to a 5% decline. This structural mix shift toward clinic services dragged gross margins down to 46.9%. While aggressive operating expense control narrowed the net loss and significantly improved cash burn compared to a year ago, the balance sheet remains tight with $19.0 million in total cash. Q2 guidance for 'mid-single digit' growth signals a decelerating top-line trajectory as the company laps the Greenbrook acquisition anniversary.
🐂 Bull Case
Operating expenses fell 6% YoY to $25.1 million. This cost discipline slashed Q1 operating cash burn from $17.0 million last year to $9.4 million this quarter, proving the company can leverage its scale.
Optum/UHC's decision to allow Psychiatric Mental Health Nurse Practitioners (PMHNPs) to administer NeuroStar opens access to nearly 35 million covered lives across 26 states, alleviating psychiatric staffing bottlenecks.
🐻 Bear Case
As lower-margin clinic revenue outpaces legacy capital and consumable sales, gross margins compressed from 49.2% to 46.9%. Management's FY26 guidance indicates this is the new normal.
Despite a larger installed base and clinic network, U.S. treatment session revenue dropped 5%. This signals potential cannibalization or underutilization across the legacy independent provider network.
⚖️ Verdict: ⚪
Neutral. Management is executing well on expense control and clinic integration, but the decelerating top-line guidance and shrinking standalone treatment session volumes limit near-term upside. The path to profitability relies entirely on halting the remaining cash burn before the $19M cash balance runs out.
Key Themes
U.S. Clinics Driving Top-Line Output
The Greenbrook clinic network remains the primary growth engine. U.S. clinic revenue grew 15% YoY to $21.5 million, accounting for 62% of total revenue. This shift from a capital equipment manufacturer to a vertically integrated healthcare provider is stable and anchoring the top line.
Nurse Practitioner Policy Unlocks Capacity
A major technological and operational innovation hurdle has been cleared: Optum/UHC/UBH expanded its clinical policy to allow PMHNPs to order and administer NeuroStar Advanced Therapy. This applies to states with full practice authority, reaching ~34.8 million lives. This allows Neuronetics to scale clinic throughput without the prohibitively high costs and scarcity of licensed psychiatrists.
Aggressive OpEx Control Improves Burn
Management's commitment to cost synergies is accelerating. Q1 operating expenses were $25.1 million, down 6% YoY, driven by reductions in general, administrative, sales, and marketing expenses. This discipline resulted in a $7.6 million YoY reduction in operating cash burn.
Legacy Treatment Sessions Reversing
Contradicting the bullish narrative of clinic expansion, U.S. treatment session revenue reversed course, falling 5% YoY from $9.6M to $9.1M. If the company is actively cannibalizing independent NeuroStar accounts to feed its company-owned Greenbrook clinics, the underlying health of the legacy consumables business is severely compromised.
Margin Compression from Mix Shift
Gross margin decelerated to 46.9% in Q1 2026, down from 49.2% a year ago and a far cry from the ~75% margins the company enjoyed before acquiring Greenbrook. As service-based revenue overtakes high-margin consumable packs, the company will require significantly higher volume to drop the same dollars to the bottom line.
Decelerating Revenue Growth
After posting triple- and double-digit growth in 2025 due to the Greenbrook acquisition, growth is rapidly decelerating. Q1 landed at 8% YoY, and management guided Q2 for 'mid-single digits'. Furthermore, International revenue collapsed 54% YoY to just $228K, effectively rendering the business a U.S.-only play.
Consolidating Mental Health Care Delivery
From a macro perspective, Neuronetics is positioning itself at the center of the mental health supply chain. By pairing NeuroStar hardware with the Greenbrook clinic footprint and layering in complementary pharmacological treatments like SPRAVATO (esketamine), the company is morphing into a full-stack mental health service provider rather than a pure-play med-tech vendor.
Other KPIs
A stable improvement from the -$17.0 million burn in Q1 2025. However, this operational burn, combined with a $5.0 million debt principal payment, drove total cash down from $34.1 million at year-end to $19.0 million. The margin for error is shrinking.
Accelerating slightly compared to 31 units shipped in Q1 2025. Revenue for this segment grew 13% to $3.2 million, implying average selling prices remain stable and healthy in the $90,000 to $94,000 range.
Decreased from $65.8 million at the end of 2025 following a $5.0 million principal payment to Perceptive Advisors. This move incurred a $0.5 million extinguishment loss but reduces ongoing interest expense burdens, crucial for a company focused on conserving cash.
Guidance
Decelerating significantly. Based on Q2 2025 revenue of $38.1 million, mid-single digit growth implies roughly $39.5 to $40.5 million. This indicates organic volume growth is sluggish following the lapping of the Greenbrook acquisition.
Stable compared to prior long-term targets. The midpoint ($163M) implies roughly 9% YoY growth versus FY25's ~$149 million. Achieving this relies heavily on Q3 and Q4 performance, given the tepid Q1 actuals and Q2 guide.
Stable vs Q1 2026 actuals (46.9%) but confirms that the high-margin profile of the legacy equipment business is permanently diluted by the clinical service mix.
Accelerating improvement expected in the back half. Because Q1 2026 already consumed $9.4 million, achieving the full-year target of -$13M to -$17M mathematically requires the company to run near cash-flow breakeven for the remaining three quarters of the year.
Key Questions
Treatment Session Decline Mechanics
U.S. treatment session revenue dropped 5% despite a 10% increase in system placements and an expanded installed base. Are we seeing direct cannibalization where independent providers are losing patient volume to company-owned Greenbrook locations?
Cash Runway and Debt Obligations
With $19 million in total cash and an implied $3.6M to $7.6M of operating burn remaining for the year, liquidity is tight. What is the minimum cash threshold required by your debt covenants, and what contingency plans are in place if Q4 fails to generate positive cash flow?
Nurse Practitioner Rollout Timeline
The Optum/UHC policy expansion for Nurse Practitioners is a massive TAM unlock. How quickly can this be operationalized across the Greenbrook footprint, and does it require near-term investments in training and credentialing?